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A B S T R A C T
Purpose
Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active
epidermal growth factor receptor tyrosine kinase inhibitor, may enhance antitumor efficacy of cytotoxics,
and combination with paclitaxel and carboplatin had acceptable tolerability in a phase I trial. Gefitinib
monotherapy demonstrated unparalleled antitumor activity for a biologic agent, with less toxicity than
docetaxel, in phase II trials in refractory, advanced non–small-cell lung cancer (NSCLC). This phase III,
randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in
chemotherapy-naive patients with advanced NSCLC.
Patients and Methods
Patients received paclitaxel 225 mg/m2 and carboplatin area under concentration/time curve of 6
mg/min/mL (day 1 every 3 weeks) plus gefitinib 500 mg/d, gefitinib 250 mg/d, or placebo. After a
maximum of six cycles, daily gefitinib or placebo continued until disease progression. End points
included overall survival, time to progression (TTP), response rate (RR), and safety evaluation.
Results
A total of 1,037 patients were recruited. Baseline demographic characteristics were well balanced. There
was no difference in overall survival (median, 8.7, 9.8, and 9.9 months for gefitinib 500 mg/d, 250 mg/d,
and placebo, respectively; P  .64), TTP, or RR between arms. Expected dose-related diarrhea and skin
toxicity were observed in gefitinib-treated patients, with no new significant/unexpected safety findings
from combination with chemotherapy. Subset analysis of patients with adenocarcinoma who received
 90 days’ chemotherapy demonstrated statistically significant prolonged survival, suggesting a gefitinib
maintenance effect.
Conclusion
Gefitinib showed no added benefit in survival, TTP, or RR compared with standard chemotherapy alone.
This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and
II monotherapy trials.
J Clin Oncol 22:785-794. © 2004 by American Society of Clinical Oncology
INTRODUCTION
Lung cancer is the most common cause of
cancer death worldwide [1]. Current first-
line chemotherapy options for patients with
advanced non–small-cell lung cancer
(NSCLC), such as the combination of a plat-
inum-based agent with paclitaxel, gemcitab-
ine, vinorelbine, or docetaxel, have substan-
tial toxicity and seem to have reached a
plateau in terms of efficacy. A randomized
study by the Southwest Oncology Group
showed that paclitaxel with carboplatin has
similar efficacy to vinorelbine with cisplatin
(median survival, 8 months for both regi-
mens; 1-year survival, 38% and 36%, re-
spectively) [2]. More recently, a study by the
Eastern Cooperative Oncology Group found
that four different platinum-based regimens
had similar efficacies [3]. Clearly, improve-
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ment on these existing treatments for advanced NSCLC is
needed, requiring the development of new agents with a dif-
ferent mechanism of action and an improved safety profile
compared with chemotherapy.
The orally active epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor gefitinib (Iressa, ZD1839;
AstraZeneca, Wilmington, DE) blocks signal transduction
pathways implicated in the proliferation and survival of
cancer cells [4]. Four phase I studies have shown that
gefitinib is generally well tolerated, with evidence of antitu-
mor activity in a range of tumors including NSCLC [5-8].
Observations and pharmacokinetic data from these trials
identified two doses for further study: gefitinib 250 mg/d is
higher than the lowest dose at which clinical response was
seen, and 500 mg/d is the highest dose level to be tolerated
long-term by most patients. Two large phase II gefitinib
monotherapy studies (Iressa Dose Evaluation in Advanced
Lung Cancer [IDEAL] 1 and 2) in patients with pretreated
advanced NSCLC further confirmed that this agent was
generally well tolerated and produced durable, clinically
significant antitumor activity (response rates for gefitinib
250 mg/d were 18.4% and 11.8% for IDEAL 1 and 2, respec-
tively), with improvement in disease-related symptoms ob-
served in approximately 40% of symptomatic patients
[9-11]. These response rates for patients receiving second-
line and higher therapy were encouraging, particularly
when considered in the context of the retrospective analysis
by Massarelli et al [12], in which the response rate declined
with each line of therapy (second line, 16.3%; third line,
2.3%). The most frequent drug-related adverse events ob-
served in these two trials were skin rash and diarrhea, which
were generally mild (grade 1 and 2). The results of random-
ized studies are awaited.
There is a strong rationale for combining gefitinib with
standard chemotherapy agents. In preclinical studies, ge-
fitinib enhanced the efficacy of cytotoxic agents against a
range of human tumor xenografts, including lung cancer,
regardless of EGFR expression [13,14]. A small phase I
study of 24 patients with chemotherapy-naı¨ve, advanced
NSCLC showed that gefitinib in combination with paclitaxel
and carboplatin was well tolerated, with no clinically signifi-
cant pharmacokinetic drug-drug interactions [15]. Together,
these preclinical data, data from gefitinib single-agent trials,
and the favorable tolerability data from the phase I trial of this
combination supported phase III investigation.
The Iressa NSCLC Trial Assessing Combination Treat-
ment (INTACT) 2 was a randomized, placebo-controlled
trial of paclitaxel and carboplatin with or without gefitinib
in chemotherapy-naive patients with advanced NSCLC.
This global multicenter study was conducted mainly (80%)
in the United States; INTACT 1, a parallel global trial that
evaluated the combination of gefitinib with gemcitabine
and cisplatin, was conducted mainly in Europe. The results
of INTACT 1 are reported elsewhere [16]. The primary
objective of INTACT 2 was to determine overall survival,
and the secondary end point was time to progression. Ad-
ditional end points included objective response rate, dis-
ease-related symptom and quality-of-life outcomes, and
adverse-event profiling.
PATIENTS AND METHODS
Eligibility Criteria
Patients were assessed by physical examination and history to
ensure that eligibility criteria were met. Entry criteria included
histologically confirmed NSCLC (cytologic specimens obtained
by brushing, washing, or needle aspiration of a defined lesion were
acceptable), unresectable stage III or IV disease, no prior chemo-
therapy, age 18 years, and performance status 0 to 2. Exclusion
criteria included the presence of mixed NSCLC or small-cell lung
cancer, brain metastases that were newly diagnosed or had not
been treated with surgery or radiation, previously treated CNS
metastases or spinal-cord compression in the absence of clinically
stable disease, less than 2 weeks since radiotherapy, unresolved
toxicity from prior radiotherapy or incomplete healing from
Fig 1. INTACT 2 trial schema. AUC,
area under concentration-time curve.
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surgery, evidence of severe systemic disease, greater than trace
blood or protein on repeat urinalysis, absolute neutrophil count
less than 2,000/L, WBCs less than 4,000/L, platelets less than
100,000/L, serum bilirubin greater than 1.25 times the upper
limit of reference range (ULRR); ALT or AST greater than 2.5
times ULRR ( five times ULRR in the presence of liver metasta-
ses), serum creatinine greater than 1.5 times ULRR, pregnancy or
breast-feeding, and hypersensitivity to mannitol, corticosteroids,
H2-antagonists, antihistamines, or agents formulated with
polyoxyethylated castor oil.
All patients gave written informed consent and approval
was obtained from the ethics committee at each trial center.
The study followed the Declaration of Helsinki [17] and good
clinical practice guidelines.
Trial Design
All patients received chemotherapy (intravenous paclitaxel
225 mg/m2 over 3 hours on day 1 of a 3-week cycle immediately
followed by intravenous carboplatin area under concentration/
time curve [18] of 6 mg/min/mL over 15 to 30 minutes on day 1)
and were randomized to receive either oral gefitinib at 250 or 500
mg/d or daily oral placebo (Fig 1). Chemotherapy was continued
for six cycles in the absence of disease progression. Thereafter,
patients were maintained on gefitinib or placebo until disease
progression or drug intolerance.
Before randomization, patients were stratified according to
weight loss in the previous 6 months ( 5% v 5%), disease stage
(III v IV), performance status (0 or 1 v 2), and the presence of
measurable disease (yes v no).
Statistical Analysis
The trial was governed by a steering committee of INTACT
principal investigators. The ongoing safety review and interim
analyses were conducted by an Independent Data Monitoring
Committee. The first interim analysis was for safety, to rule out a
detrimental survival effect for gefitinib early in the trial.
Gefitinib was compared with placebo on an intent-to-treat
basis with respect to overall survival. The study was designed to
have 90% power for a two-sided overall significance level test of
the hypothesis that gefitinib increases survival relative to placebo,
given a hazard ratio of 1.33. Assuming a 1-year survival rate of 30%
in the placebo arm, in line with the data available at the time of
Table 1. Patient Characteristics
Gefitinib 500 mg/d
(n  347)
Gefitinib 250 mg/d
(n  345)
Placebo
(n  345)
Sex, %
Female 40.1 42.3 38.6
Male 59.9 57.7 61.4
Age, years
Median 62 61 63
Range 26–82 27–86 31–85
Disease stage, %
IIIa 2.6 2.3 3.8
IIIb 15.3 16.2 17.1
Without pleural effusion 3.5 3.2 5.2
With pleural effusion 11.8 13.0 11.9
IV 81.8 81.2 78.3
WHO performance status, %
0 34.6 33.0 38.6
1 51.9 56.5 51.9
2 13.3 10.4 9.3
Weight loss in previous 6 months, %
 5% 59.1 62.6 60.9
 5% 39.5 37.1 38.3
Disease measurability, %
Measurable 93.9 91.3 88.4
Nonmeasurable 5.8 7.8 11.0
Histology, %
Squamous 16.7 20.3 19.4
Adenocarcinoma 57.9 55.7 51.9
Adenosquamous 2.9 2.3 1.7
Bronchoalveolar 2.9 2.9 3.2
Unspecified NSCLC 11.5 9.6 11.3
Large cell 7.2 8.7 11.0
Race, %
White 88.5 90.4 91.9
Black 7.5 4.1 5.2
Other 4.0 5.5 2.9
Abbreviation: NSCLC, non–small-cell lung cancer.
Information was not available for all patients.
Gefitinib  Paclitaxel/Carboplatin in NSCLC
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protocol writing, this hazard ratio equates to an increase in median
survival of 2.3 months for both gefitinib arms. The final analysis of
overall survival was planned to include 750 events. Based on the
study design assumptions, 1,029 patients were required.
At the final analysis, an adaptive survival analysis procedure
was used that tested either for a positive or negative gefitinib
dose-response relationship, based on prospective criteria applied
to the observed data. A survival trend test (global ordered log-rank
[GOLrank] test), in which the hypothesis was no effect versus the
specific ordering of placebo, gefitinib 250 mg/d, and gefitinib 500
mg/d, was used for a positive dose-response, whereas pairwise
log-rank tests would be used for a mixed dose-response [19]. To
preserve an overall two-sided 5% significance level, and to account
for the use of a survival trend test at the second interim analysis,
simulations with the adaptive procedure were used to calculate
a nominal significance level of 4.4% for the final analysis.
According to prospective criteria for the adaptive procedure,
the final analysis used a survival trend test to compare survival
between the treatment arms.
A posthoc multivariate analysis with eight prespecified prog-
nostic factors at trial entry (disease stage III v IV; performance
status 0 or 1 v 2; weight loss in prior 6 months 5% v 5%; sex;
histology; presence or absence of metastases to bone, liver, or
brain) was performed to assess which variables were predictive of
improved survival.
In a posthoc subgroup analysis, stratification and prognostic
factors (disease stage III v IV; performance status 0 or 1 v 2; weight
loss in prior 6 months  5% v  5%; presence or absence of
metastases to bone, liver, or brain) and subgroups of sex, time on
chemotherapy, and histology were analyzed in a univariate model.
An unadjusted Cox proportional hazard test was applied to the
overall survival data for each subgroup to estimate the hazard ratio
and 95% CI for the treatment comparisons of gefitinib 250 or 500
mg/d versus placebo.
Assessments
Overall survival and time to progression were assessed from
the date of randomization to the date of death (any cause) and the
date of objective disease progression (death was considered a
progression event in patients who died before disease progres-
sion), respectively. Patients without documented death or objec-
tive progression at the time of the final analysis were censored at
the date last known to be alive or their last objective tumor assess-
ment, respectively.
Tumor response was evaluated according to Response Eval-
uation Criteria In Solid Tumors, the revised version of the Inter-
national Union Against Cancer/WHO criteria [20].
During the trial, and for 30 days after the last dose of gefitinib
or placebo, patients were monitored for adverse events, graded
according to the National Cancer Institute Common Toxicity
Criteria (CTC) version 2.0. Hematology and biochemistry assess-
ments were performed 7 days before the date of randomization
and at each clinic visit. Analysis of other end points, such as
symptom improvement rate, quality of life, and correlation of
EGFR with survival, is ongoing and will be reported separately.
RESULTS
Patients
In total, 1,037 patients were recruited between May
2000 and April 2001, approximately 80% of whom were in
the United States. The baseline characteristics of the pa-
tients were similar in each of the three treatment groups
(Table 1). Most patients (approximately 80%) had meta-
static stage IV disease, and more than 50% of patients in
each group had adenocarcinoma. Approximately 20% of
patients in each of the treatment groups are confirmed to
have continued receiving chemotherapy after withdrawal
from the study.
Efficacy
At each interim analysis, the Independent Data Moni-
toring Committee made recommendations to continue the
trial. A total of 725 events (246, 232, and 247 events for
gefitinib 500 mg/d, gefitinib 250 mg/d, and placebo, respec-
tively) were observed for survival and 637 events (178, 215,
and 244 events, respectively) for time to progression, with a
minimum follow-up of 12 months for survival and 6
months for all other end points.
At the final analysis, neither dose of gefitinib improved
overall survival when added to paclitaxel and carboplatin
compared with paclitaxel and carboplatin plus placebo
(GOLrank P .6385). Median survival was 8.7, 9.8, and 9.9
months in the gefitinib 500 mg/d, gefitinib 250 mg/d, and
placebo arms, respectively (Fig 2A). The 1-year survival
Fig 2. Kaplan-Meier estimates of (A) overall survival and (B) time to
progression. GOLrank, global ordered log-rank test.
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rates were 37%, 41%, and 42%, respectively. Similarly, there
was no statistically significant difference between the three
groups in median time to progression (4.6, 5.3, and 5.0
months, respectively; GOLrank P .0562; Fig 2B).
In the posthoc multivariate analysis, performance sta-
tus of 2, weight loss, and bone and liver metastases were
significant (P .05) predictors of worse survival outcome.
Survival differences were also seen for sex and brain metasta-
ses. For the posthoc univariate analysis, generally similar pat-
terns were observed in each of the subgroup analyses, showing
no overall difference between treatment groups (P .05, not
significant; Table 2). There was no survival advantage in any of
the subgroups when gefitinib at any dose was added to chemo-
therapy. However, there was a trend toward improved survival
in the subgroup of patients with adenocarcinoma who had
received chemotherapy for  90 days (patients would have
received at least the median number of chemotherapy cycles)
in the gefitinib 250 mg/d arm (P  .05; Fig 3), suggesting a
possible effect of gefitinib monotherapy as maintenance ther-
apy. Although this trend continued for other subgroups (Table
3), the numbers were too small to yield statistical significance.
Complete responses were rare, observed in 0.6%, 2.6%,
and 1.2% of patients in the gefitinib 500 mg/d, gefitinib 250
mg/d, and placebo arms, respectively, and overall response
rates were 30.0%, 30.4%, and 28.7%, respectively, demon-
strating no statistically significant efficacy difference be-
tween treatment arms.
Duration of Therapy, Dose Adherence, and
Dose-Intensity
Patients receiving gefitinib 250 mg/d or placebo had a
longer duration of therapy than those receiving gefitinib
500 mg/d (Table 4). Similarly, the number of gefitinib dose
interruptions and reductions was highest in the gefitinib
500 mg/d arm and similar in the gefitinib 250 mg/d and
placebo arms. There was a high overall adherence to ge-
fitinib, and the median dose-intensity for both paclitaxel
and carboplatin was similar in all treatment arms (Table 4).Fig 3. Subset analysis of patients with adenocarcinoma who received 90
days of chemotherapy. GOLrank, global ordered log-rank test.
Table 2. Unadjusted Cox Proportional Hazard Model: Survival by Subgroup (ITT population)
Factor
Placebo v Gefitinib 250 mg/d Placebo v Gefitinib 500 mg/d
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Sex
Male 1.074 0.858 to 1.345 .531 1.112 0.891 to 1.388 .349
Female 0.945 0.700 to 1.277 .714 0.761 0.567 to 1.023 .070
Disease stage
III 0.986 0.651 to 1.492 .947 1.312 0.845 to 2.036 .226
IV 1.060 0.868 to 1.294 .571 0.917 0.754 to 1.114 .381
Performance status
0 or 1 1.047 0.864 to 1.269 .641 1.003 0.827 to 1.215 .980
2 0.972 0.587 to 1.610 .911 0.903 0.567 to 1.439 .668
Weight loss in the 6 months prior to entry
 5% 1.034 0.814 to 1.314 .786 0.974 0.767 to 1.237 .829
 5% 1.012 0.771 to 1.328 .933 0.951 0.728 to 1.243 .714
Histology type
Adenocarcinoma, including
bronchoalveolar carcinoma
1.156 0.905 to 1.476 .247 1.030 0.812 to 1.306 .808
Other 0.919 0.642 to 1.315 .642 0.738 0.523 to 1.042 .084
Metastases
Bone 0.835 0.595 to 1.171 .296 0.946 0.685 to 1.307 .737
Liver 1.028 0.703 to 1.503 .887 0.899 0.617 to 1.311 .580
Brain 1.727 0.727 to 4.104 .216 0.673 0.335 to 1.352 .266
Abbreviation: ITT, intention to treat.
A hazard ratio greater than 1 indicates that patients who received 250 or 500 mg/d of gefitinib live longer than those given placebo. A hazard ratio less than
1 indicates that patients who received placebo live longer than those given 250 or 500 mg/d of gefitinib.
Gefitinib  Paclitaxel/Carboplatin in NSCLC
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Safety and Tolerability
Most adverse events occurred during combination
treatment and many were attributed to chemotherapy. The
safety profile of gefitinib from the monotherapy phase of
the trial was similar to that seen in the phase II program.
The most common adverse events were gastrointestinal,
skin-related, and hematologic in nature. The incidence of
acne and rash by grade is shown in Table 5; most of these
events were mild (grade 1 or 2). Hematologic adverse events
occurred with similar incidence in all three treatment
groups, consistent with the toxicity profile of chemother-
apy. Gefitinib did not seem to exacerbate these toxicities.
Interstitial lung disease (ILD)–type events were experienced
by 1.5%, 2.1% and 0.9% of patients in the gefitinib 500
mg/d, gefitinib 250 mg/d, and placebo arms, respectively,
and the incidence of dyspnea and other pulmonary adverse
events such as cough and pneumonia were generally similar
across treatment arms (Table 6). For those adverse events
considered to be drug-related (possibly related to gefitinib
or placebo), there was a gefitinib dose-response relationship
for skin and gastrointestinal events (Table 7). The most
frequent grade 3 or 4 drug-related adverse events were
diarrhea and rash, which occurred at a higher incidence in
the gefitinib 500 mg/d arm than in the gefitinib 250 mg/d or
placebo arms (Table 7). Statistical analysis of prespecified
adverse events during the chemotherapy phase revealed no
difference between treatment arms except for diarrhea (P
.0001 for gefitinib 500 mg/d v gefitinib 250 mg/d or placebo;
P  .0011 for gefitinib 250 mg/d v placebo), defined skin
events (P  .0001 for gefitinib 500 mg/d v gefitinib 250
mg/d; P  .0001 for gefitinib 500 mg/d or gefitinib 250
mg/d v placebo), and CTC grade 3 and 4 infectious events
(predominantly sepsis and febrile neutropenia, rather than
any specific or localized infections; P  not significant for
gefitinib 500 mg/d v gefitinib 250 mg/d; P  .0099 for
gefitinib 500 mg/d v placebo; P .022 for gefitinib 250 mg/d v
placebo). No adjustments were made to the P values in these
analyses to take account of the multiple comparisons.
Posthoc analyses were performed to assess the survival
status for patients with specific rash and diarrhea events.
The first analysis was performed in a subgroup of patients
with any CTC grade event with Coding Symbols for a
Thesaurus of Adverse Reaction Terms of acne, rash, or dry
skin. The second analysis was performed in a subgroup of
patients with CTC grade2 events (specifically acne, rash, dry
skin, and diarrhea). Neither posthoc analysis showed a differ-
ence in overall survival between the three treatment groups.
Only six deaths were considered to be drug-related:
three patients in the gefitinib 500 mg/d arm (sudden death,
intestinal obstruction, and dehydration plus kidney fail-
ure); one in the gefitinib 250 mg/d arm (pulmonary embo-
lus); and two in the placebo arm (sepsis and cerebral vascu-
lar accident). The type of adverse events leading to
withdrawal were similar in all three treatment groups, the
most common being diarrhea. Fewer patients discontinued
therapy because of adverse events (any cause) in the ge-
Table 3. Landmark Analyses
Chemotherapy
No. of
Patients
Median Survival (months)
Gefitinib 500 mg/d Gefitinib 250 mg/d Placebo
 90 days 599 14.1 14.9 13.0
 90 days  adenocarcinoma 334 16.1 17.1 13.6
 90 days  stage IV disease 458 12.0 15.1 12.6
 90 days  adenocarcinoma  stage IV disease 260 13.7 19.7 12.5
Table 4. Duration of Therapy, Dose Adherence, and Dose-Intensity
Gefitinib 500 mg/d
(n  342)
Gefitinib 250 mg/d
(n  342)
Placebo
(n  341)
Gefitinib
Median duration of gefitinib/placebo therapy, days 99 129 138
Dose interruption, % 55.0 26.3 20.5
Dose reduction, % 28.9 8.2 3.2
Median dose adherence, % 92.2 98.9 99.5
Chemotherapy
Median no. of chemotherapy cycles 5 5 6
Paclitaxel median dose-intensity, % 95.3 96.0 96.1
Carboplatin median dose-intensity, % 85.8 87.4 88.5
NOTE. Data are for population assessable for safety.
Percentage of patients with at least one dose interruption or reduction.
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fitinib 250 mg/d and placebo groups (10.5% and 7.9%,
respectively) than in the gefitinib 500 mg/d group (22.5%).
DISCUSSION
This large, randomized, placebo-controlled trial examined
the efficacy and safety of gefitinib in combination with
paclitaxel and carboplatin for the front-line therapy of ad-
vanced NSCLC. The data from 1,037 patients demonstrate
that combination of conventional chemotherapy with ge-
fitinib did not improve patient survival, disease-free sur-
vival, or response rate compared with chemotherapy given
alone. Results with gefitinib 250 mg/d were similar to those
in the placebo arm, whereas gefitinib 500 mg/d tended
toward a worse outcome, although it was not statistically
different from placebo. Median survival was 8.7, 9.8, and
9.9 months in the gefitinib 500 mg/d, gefitinib 250 mg/d,
and placebo arms, respectively. These results are disap-
pointing and surprising in view of recent results obtained
with the phase II studies of single-agent gefitinib in recur-
rent NSCLC (IDEAL 1 and 2). Tumor response rates of
11.8% to 18.4% and a clinically meaningful symptom im-
provement of approximately 40% were reported [9,11].
However, in contrast to the current study in chemotherapy-
naive patients, the phase II studies recruited patients with
recurrent or refractory disease after prior chemotherapy
regimens that included platinum. It has yet to be deter-
mined whether this difference in patient population alone
influenced the lack of additional response seen in our study.
It could be speculated that recurrent NSCLC uses EGFR
ligands as potential survival factors after platinum-based
chemotherapy, as it has been reported that EGF stimulates
production of the survival factor vascular endothelial
growth factor [21,22]. Recent results show that two phase
III trials of first-line erlotinib in combination with standard
chemotherapy in patients with metastatic NSCLC did not
meet their primary end point of improving overall survival.
The current results are also surprising given the strik-
ing results reported for gefitinib in combination with che-
motherapy in animal models [13,14]. Given our findings,
the relevance of animal models to human cancers should be
carefully examined, as experimental preclinical results fre-
quently do not translate to the clinic. One factor is the lower
doses of chemotherapy agents often used in animal models
to observe a synergy with biologic therapies. We used the
maximum therapeutic dose of carboplatin and paclitaxel in
this human trial, which might have negated this effect.
Another limitation is related to tumor implantation in the
animal models. Rather than orthotopic tumors, most re-
searchers use subcutaneous ectopic tumor implants, which
are devoid of interaction with the true microenvironment
of lung cells, and this could specifically alter tumor growth
in vivo and perhaps the response to these agents [23,24].
Additionally, many of these cells are implanted only a short
time before the start of therapy, which is, of course, much
different from the human situation. These unrealistic
growth patterns may also alter the response to therapy.
Interestingly, the subset analysis of adenocarcinoma pa-
tients who received  90 days of chemotherapy suggests
that patients receiving gefitinib 250 mg/d who completed
therapy had some long-term survival benefits, indicating
that gefitinib might be effective as a cytostatic agent in
humans, maintaining tumor regression after chemother-
apy. This may be due to the ability of gefitinib to block
EGFR-dependent survival pathways or possibly due to en-
hancement of apoptosis. However, this was not seen to the
same significant extent in INTACT 1 [16]. These analyses
were done posthoc and suffer from selection factors. Fur-
thermore, as many analyses were performed for different
subgroups, it is possible that observed effects could have
appeared by chance alone. Perhaps the best use of gefitinib
in vivo will be in sequence with chemotherapy. This hy-
pothesis can be tested in randomized trials, and plans are
underway to initiate such trials. Several options exist, in-
Table 5. Skin Reactions by Grade
% of Patients
Gefitinib 500 mg/d
(n  342)
Gefitinib 250 mg/d
(n  342)
Placebo
(n  341)
Rash
None 26.0 40.0 55.1
Grade 1 32.2 40.4 32.0
Grade 2 29.8 15.8 11.4
Grade 3 11.1 3.8 1.5
Grade 4 0.9 0 0
Acne
None 73.1 79.0 90.6
Grade 1 10.5 14.0 7.3
Grade 2 11.4 6.1 2.1
Grade 3 4.4 0.9 0
Grade 4 0.6 0 0
Rash or acne
None 20.8 33.6 51.9
Grade 1 33.0 42.1 33.7
Grade 2 31.6 19.6 12.9
Grade 3 13.7 4.7 1.5
Grade 4 0.9 0 0
Table 6. Pulmonary Adverse Events
Gefitinib 500 mg/
d (n  342)
Gefitinib 250 mg/d
(n  342)
Placebo
(n  341)
Dyspnea, % 34.2 36.5 32.6
Cough, % 26.6 27.8 24.3
Pneumonia, % 8.5 8.2 8.5
ILD event, n 5 7 3
Abbreviation: ILD, interstitial lung disease.
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cluding first-line gefitinib followed by chemotherapy, ge-
fitinib maintenance therapy after response to chemother-
apy or radiotherapy, or adjuvant gefitinib after surgery or
radiotherapy for early-stage disease.
This trial was the first placebo-controlled study to ad-
dress the question of gefitinib safety, and it confirms the
safety profile from phase I and II monotherapy trials. Diar-
rhea and skin toxicity were milder and less frequently re-
ported in the 250 mg/d dose group than in the 500 mg/d
group. The frequency of other gastrointestinal side effects
was relatively low and similar to the placebo arm. With the
exception of mild-to-moderate diarrhea and skin-related
events, the gefitinib 250 mg/d arm exhibited a safety profile
similar to the placebo arm. Recently, ILD has been reported
for four of 18 patients treated with gefitinib for NSCLC, two
of whom died [25]. The same incidence was not seen in this
randomized controlled study, in which the incidence of
ILD-type events was similar in all treatment arms. The
favorable tolerability of gefitinib is further supported by the
high overall dose adherence. In addition, no change of the
expected chemotherapy-related toxicity was observed in the
gefitinib-treated arms. Other than dose-response effects, no
predisposition factors for gefitinib toxicity were identified,
and it can be concluded that gefitinib 250 mg/d has an
acceptable safety profile when administered alone or in
combination with chemotherapy. Similar results were seen
in the INTACT 1 study [16].
Another possible explanation for the lack of a survival
difference seen in this study is that patients were not se-
lected on entry for sensitivity to the study agent (in large
part because a sensitivity assay does not yet exist). High
expression of EGFR has been associated with lower relapse-
free and overall survival rates in several malignancies in
retrospective studies [26]. However, sensitivity to anti-
EGFR therapy does not seem to be correlated with expres-
sion of this receptor [27], and conflicting results regarding
the relationship between receptor expression and the effi-
cacy of gefitinib have been reported [14,28-31]. It is possible
that only patients with upregulated signal transduction
pathways along the EGFR axis, such as the Akt pathway,
might benefit. Patient selection was important in the use of
trastuzumab in metastatic breast cancer, where a positive
result with chemotherapy was seen in the subgroup of pa-
tients who had significant overexpression of the target [32].
At this time there is no standard method to detect
EGFR, HER2, and their phosphorylated forms. Evaluation
of the biology of NSCLC tumors treated with gefitinib is
currently underway to identify the targets and mechanisms
of response and resistance to therapy. Results from the 480
samples collected from patients enrolled in this study will be
provided in a separate report. Exploratory analysis of tumor
biopsies taken from patients in the IDEAL 1 and 2 trials
used a reproducible immunohistochemical assay to esti-
mate the correlation of EGFR membrane staining intensity
(no, weak, moderate, or strong staining [0, 1, 2, 3,
respectively]) with the probability of objective tumor re-
sponse or symptom improvement, with the null hypothesis
that membrane staining intensity is not predictive of clini-
cal outcome [33,34]. The mean proportion of cells staining
2 or 3 was 31.3% for patients with response and 37.5%
Table 7. Common Drug-Related Adverse Events (% of patients)
% of Patients
Gefitinib 500 mg/d (n  342) Gefitinib 250 mg/d (n  342) Placebo (n  341)
All Grade 3 or 4 All Grade 3 or 4 All Grade 3 or 4
Diarrhea 69.3 25.4 58.2 9.9 29.3 2.9
Rash 67.3 11.7 54.4 3.2 37.5 1.5
Acne 26.3 5.0 19.9 0.9 7.3 0
Dry skin 25.7 1.5 15.2 0.3 4.4 0
Pruritus 20.5 1.8 15.2 0.6 12.6 0.3
Nausea 18.7 4.1 19.3 1.8 14.7 2.1
Vomiting 12.9 2.9 11.7 2.0 9.4 2.3
Anorexia 11.7 0.6 7.0 0.6 6.2 0.3
Asthenia 11.1 2.3 13.5 0.3 10.3 1.2
Dehydration 9.9 5.0 3.8 1.8 2.9 1.8
Neutropenia 7.0 6.1 7.9 6.7 5.9 5.9
Anemia 6.7 1.2 6.4 0.6 2.6 0.6
Neuropathy 4.1 0.9 5.3 0.3 5.9 0.9
Leukopenia 3.2 2.3 5.3 2.0 3.8 2.1
Conjunctivitis 6.4 0.6 5.3 0 3.2 0
Alopecia 1.5 0 4.7 0 4.7 0
Dyspnea 0.9 0.3 0.9 0.6 1.5 0.3
Possibly related to gefitinib/placebo.
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for those without response. Furthermore, in both IDEAL
trials, five (15%) of 34 patients had response with less than
10% detectable staining. The mean percentage with 3
staining was 32.1% for patients with and 22.8% for patients
without symptom improvement. Therefore, the results of
this analysis did not reveal a consistent association between
EGFR membrane staining and either objective response or
symptom improvement.
Although the current INTACT 2 study did not show
superior efficacy when gefitinib was added to paclitaxel and
carboplatin, the overall safety profile of gefitinib was con-
firmed. These data contribute to a better understanding of
the optimal use of gefitinib as monotherapy in refractory
disease and potentially in sequence with chemotherapy for
previously untreated patients with NSCLC.
  
Appendix
The appendix is included in the full-text version of this
article, available on-line at www.jco.org. It is not included
in the PDF (via Adobe® Acrobat Reader®) version.
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